Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases. Neuraltus has three clinical-stage programs in its development pipeline, each of which is advancing novel drug molecules that represent new, first-in-class approaches to treating the Company’s target disease indications:

• NP001, a novel, proprietary approach that regulates macrophage activation, targeting diseases including amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease), Parkinson’s disease, Alzheimer’s disease and multiple sclerosis. Neuraltus completed a Phase 1 clinical trial of NP001 for ALS in November 2010. Neuraltus initiated Phase 2 clinical testing in April 2011.
• NP002, a small molecule, nicotinic receptor agonist designed to reduce dyskinesias (muscle movement disorders) that are a primary side effect of L-dopa treatment of Parkinson’s. A Phase1/2 trial was completed in November 2010.
• NP003, an orally bioavailable, small molecule designed to treat lysosomal storage diseases, such as Fabry’s disease and Gaucher’s disease, and which also is expected to have application in Parkinson’s disease. IND-enabling, preclinical studies are ongoing, with Phase 1/2 clinical testing expected to begin in 2012.

Neuraltus began operations in 2009 based on a broadly enabling technology portfolio and intellectual property assembled by the company founders, Michael McGrath, MD, PhD, Professor of Laboratory Medicine at the University of California, San Francisco; Edgar Engleman, MD, Professor of Medicine and Pathology at Stanford University School of Medicine, and Ari Azhir, PhD. In March 2009 Neuraltus closed a $17M Series A financing with leading venture groups Adams Street Partners, Latterell Venture Partners and VantagePoint Venture Partners.